U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07037680) titled 'Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT' on May 28.
Brief Summary: Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year ...